- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05711394
Een studie om de bijwerkingen en verandering in ziekteactiviteit van orale Atogepant-tabletten te beoordelen bij pediatrische deelnemers (6-17 jaar) met episodische migraine
Een fase 3, multicenter, 12 weken durend, dubbelblind, placebogecontroleerd onderzoek ter evaluatie van de veiligheid en werkzaamheid van Atogepant voor de preventieve behandeling van episodische migraine bij pediatrische proefpersonen van 6-17 jaar.
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric participants between the ages of 6 and 17.
Atogepant is a medicine currently approved to treat adults with migraine (0 to 14 migraine days per month) and is being studied in pediatric participants between the ages of 6 and 17 with a history of episodic migraine. This is a Phase 3, randomized, double-blind study of atogepant in participants with a history of episodic migraine with an open-label pharmacokinetic substudy. Eligible participants will be randomized into 6 different groups. Participants between the ages of 12 and 17 will be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. Participants between the ages of 6 and 11 will also be randomized to receive placebo, low-dose atogepant, or high-dose atogepant for 12 weeks. The specific atogepant doses to be used in participants between the ages of 6 and 11 will be determined after the PK substudy is complete. Around 450 participants will be enrolled in approximately 100 sites worldwide.
Placebo, low-dose atogepant, and high-dose atogepant are given as a tablet to take by mouth once a day. At the end of Week 12, participants will either undergo a follow-up visit 4 weeks after last study treatment or join an extension study where they can continue to receive atogepant for another 52 weeks.
There may be a bigger responsibility for participants in this study. Participants will attend regular visits during the study at a hospital or clinic. The effects of treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: ABBVIE CALL CENTER
- Telefoonnummer: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Studie Locaties
-
-
Antwerpen
-
Edegem, Antwerpen, België, 2650
- Werving
- Uza /Id# 247339
-
-
West-Vlaanderen
-
Bruges, West-Vlaanderen, België, 8000
- Werving
- Algemeen Ziekenhuis Sint-Jan Brugge /ID# 247201
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Werving
- Stollery Children's Hospital /ID# 249672
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Werving
- London Health Sciences Center- University Hospital /ID# 252979
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Voltooid
- McGill University Health Centre - Glen Site /ID# 247271
-
-
-
-
Capital Region
-
Herlev, Capital Region, Denemarken, 2730
- Werving
- Herlev Hospital /ID# 247724
-
-
Central Jutland
-
Herning, Central Jutland, Denemarken, 7400
- Werving
- Regionshospitalet Godstrup /ID# 247902
-
Contact:
- Site Coordinator
- Telefoonnummer: +45 50935730
-
-
North Denmark
-
Aalborg, North Denmark, Denemarken, 9000
- Voltooid
- Aalborg Sygehus Nord /ID# 247428
-
-
-
-
-
Toulouse, Frankrijk, 31059
- Voltooid
- CHU Toulouse - Hôpital des enfants /ID# 247553
-
-
Somme
-
Amiens, Somme, Frankrijk, 80054
- Voltooid
- CHU Amiens-Picardie Site Sud /ID# 248833
-
-
Val-de-Marne
-
Créteil, Val-de-Marne, Frankrijk, 94000
- Voltooid
- Centre Hosp Intercommunal de Creteil /ID# 248832
-
-
-
-
-
Budapest, Hongarije, 1085
- Werving
- Semmelweis Egyetem /ID# 248360
-
Budapest, Hongarije, 1024
- Voltooid
- MIND Clinic /ID# 248687
-
-
-
-
-
Haifa, Israël, 3339419
- Werving
- Bnai Zion Medical Center /ID# 247469
-
-
Central District
-
Beer Ya'akov, Central District, Israël, 70300
- Werving
- Shamir Medical Center /ID# 256857
-
-
Haifa District
-
Hadera, Haifa District, Israël, 38100
- Voltooid
- Hillel Yaffe Medical Center /ID# 246747
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israël, 5265601
- Werving
- The Chaim Sheba Medical Center /ID# 246746
-
Tel Aviv, Tel Aviv, Israël, 6423906
- Werving
- Tel Aviv Sourasky Medical Center /ID# 247466
-
-
-
-
-
Palermo, Italië, 90127
- Werving
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 247638
-
-
Milano
-
Milan, Milano, Italië, 20133
- Werving
- Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 247581
-
-
Roma
-
Rome, Roma, Italië, 00165
- Werving
- Ospedale Pediatrico Bambino Gesu /ID# 247647
-
-
-
-
-
Kyoto, Japan, 600-8811
- Werving
- Tatsuoka Neurology Clinic /ID# 254455
-
-
Hyōgo
-
Kobe, Hyōgo, Japan, 658-0064
- Werving
- Konan Medical Center /ID# 254457
-
Nishinomiya, Hyōgo, Japan, 663-8204
- Werving
- Yamaguchi Clinic /ID# 254753
-
-
Kochi
-
Kochi, Kochi, Japan, 780-8011
- Werving
- Umenotsuji Clinic /ID# 254453
-
-
Miyagi
-
Sendai, Miyagi, Japan, 982-0014
- Werving
- Sendai Headache and Neurology Clinic Medical Corporation /ID# 254211
-
-
Osaka
-
Osaka, Osaka, Japan, 556-0015
- Werving
- Tominaga Clinic - Osaka /ID# 254450
-
-
Tokyo
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Werving
- Tokyo Medical University Hospital /ID# 254459
-
-
-
-
Gelderland
-
Nijmegen, Gelderland, Nederland, 6532 SZ
- Werving
- Canisius-Wilhelmina Ziekenhuis /ID# 253065
-
-
South Holland
-
The Hague, South Holland, Nederland, 2545 AA
- Werving
- HagaZiekenhuis /ID# 247318
-
-
Zeeland
-
Terneuzen, Zeeland, Nederland, 4535 PA
- Werving
- ZorgSaam Zorggroep Zeeuws-Vlaanderen /ID# 247301
-
-
-
-
-
Wroclaw, Polen, 52-210
- Werving
- MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 247381
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polen, 60-848
- Werving
- Clinical Research Center Medic-R /ID# 247383
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-752
- Werving
- Athleticomed Sp. z o.o /ID# 248789
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-539
- Werving
- Specjalistyczne Gabinety Sp. z o.o. /ID# 247384
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-582
- Werving
- Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 247382
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 01-018
- Werving
- Oha-Med Sp. Z O.O /ID# 248614
-
-
-
-
-
Bayamón, Puerto Rico, 00960
- Voltooid
- Clinical Research Investigator Group /ID# 261254
-
Caguas, Puerto Rico, 00727
- Voltooid
- Dr. Samuel Sanchez PSC /ID# 248495
-
Dorado, Puerto Rico, 00646
- Werving
- Puerto Rico Health Institute /ID# 249741
-
Contact:
- Site Coordinator
- Telefoonnummer: 787-797-1049
-
San Juan, Puerto Rico, 00927
- Voltooid
- PRCCI Clinical Research Center /ID# 262726
-
San Juan, Puerto Rico, 00918-3501
- Voltooid
- Caribbean Medical Research Center Headlands /ID# 251634
-
-
-
-
-
Bucharest, Roemenië, 014146
- Voltooid
- Delta Health Care S.R.L /ID# 248130
-
-
Bucharest
-
Bucharest, Bucharest, Roemenië, 022102
- Voltooid
- Spitalul Clinic de Copii Dr. Victor Gomoiu /ID# 248431
-
-
Cluj
-
Cluj-Napoca, Cluj, Roemenië, 400012
- Voltooid
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca /ID# 248595
-
-
-
-
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitario Vall de Hebron /ID# 247967
-
Madrid, Spanje, 28040
- Werving
- Hospital Clinico San Carlos /ID# 249267
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 de Octubre /ID# 275578
-
Seville, Spanje, 41013
- Voltooid
- Hospital Universitario Virgen del Rocio /ID# 248632
-
Valencia, Spanje, 46026
- Voltooid
- Hospital Universitario y Politecnico La Fe /ID# 247969
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB15 6RE
- Werving
- NHS Grampian /ID# 249067
-
Stockport, Verenigd Koninkrijk, SK2 7JE
- Werving
- Stepping Hill Hospital-Stockport NHS foundation trust /ID# 261121
-
-
Greater London
-
London, Greater London, Verenigd Koninkrijk, WC1N 3HZ
- Werving
- Great Ormond Street Children's Hospital /ID# 262933
-
-
Kent
-
Gillingham, Kent, Verenigd Koninkrijk, ME7 5NY
- Werving
- Medway NHS Foundation Trust /ID# 249065
-
-
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35805-4046
- Werving
- Rehabilitation & Neurological Services /ID# 248517
-
Saraland, Alabama, Verenigde Staten, 36571
- Werving
- The Center for Clinical Trials - Saraland /ID# 271604
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72211
- Werving
- Preferred Research Partners /ID# 249729
-
Little Rock, Arkansas, Verenigde Staten, 72211
- Voltooid
- Preferred Research Partners /ID# 270406
-
-
California
-
Anaheim, California, Verenigde Staten, 92805
- Werving
- Advanced Research Center /ID# 251381
-
Long Beach, California, Verenigde Staten, 90807
- Werving
- Alliance for Research Alliance for Wellness /ID# 248521
-
Oceanside, California, Verenigde Staten, 92056
- Voltooid
- Excell Research, Inc /ID# 247532
-
San Jose, California, Verenigde Staten, 95124-4108
- Werving
- Lumos Clinical Research Center /ID# 249731
-
Walnut Creek, California, Verenigde Staten, 94596
- Werving
- Sunwise Clinical Research /ID# 248529
-
-
Colorado
-
Fort Collins, Colorado, Verenigde Staten, 80528
- Voltooid
- Advanced Neurosciences Research, LLC /ID# 247592
-
-
Florida
-
Gulf Breeze, Florida, Verenigde Staten, 32561-4495
- Voltooid
- Northwest Florida Clinical Research Group, LLC /ID# 251382
-
Homestead, Florida, Verenigde Staten, 33030-4613
- Voltooid
- Advanced Research Institute of Miami /ID# 248539
-
Miami, Florida, Verenigde Staten, 33155
- Werving
- My Preferred Research LLC /ID# 249720
-
Spring Hill, Florida, Verenigde Staten, 34609-5692
- Voltooid
- FWD Clinical Research - Spring Hill /ID# 248525
-
-
Georgia
-
Brunswick, Georgia, Verenigde Staten, 31520-1601
- Werving
- Coastal Georgia Child Neurology /ID# 249733
-
Contact:
- Site Coordinator
- Telefoonnummer: 770-376-7912
-
-
Indiana
-
Newburgh, Indiana, Verenigde Staten, 47630
- Werving
- Deaconess Clinic - Gateway Health Center /ID# 247589
-
Contact:
- Site Coordinator
- Telefoonnummer: 812-474-7184
-
-
Kansas
-
Overland Park, Kansas, Verenigde Staten, 66210-2761
- Voltooid
- College Park Family Care Center Overland Park /ID# 249734
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48104-5131
- Werving
- Michigan Headache & Neurological Institute (MHNI) /ID# 247468
-
Contact:
- Site Coordinator
- Telefoonnummer: 734-677-6000
-
-
Mississippi
-
Ridgeland, Mississippi, Verenigde Staten, 39157
- Werving
- Proven Endpoints LLC /ID# 258066
-
Contact:
- Site Coordinator
- Telefoonnummer: 601-790-1811
-
-
Nebraska
-
Papillion, Nebraska, Verenigde Staten, 68046-4131
- Voltooid
- Cognitive Clinical Trials (CCT) - Papillion /ID# 248536
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Werving
- Goryeb Childrens Hospital /ID# 249724
-
-
New York
-
Amherst, New York, Verenigde Staten, 14226
- Werving
- Dent Neurologic Institute - Amherst /ID# 248534
-
Contact:
- Site Coordinator
- Telefoonnummer: 716-558-5670
-
New York, New York, Verenigde Staten, 10001
- Voltooid
- Modern Migraine MD /ID# 258074
-
-
North Carolina
-
Greensboro, North Carolina, Verenigde Staten, 27405
- Werving
- Headache Wellness Center /ID# 251018
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten, 45215-2123
- Werving
- Patient Priority Clinical Sites, LLC /ID# 247535
-
Contact:
- Site Coordinator
- Telefoonnummer: 513-791-7760
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Werving
- Cincinnati Childrens Hospital Medical Center /ID# 258070
-
West Chester, Ohio, Verenigde Staten, 45069
- Voltooid
- CincyScience /ID# 249726
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73112
- Voltooid
- Lynn Institute of Oklahoma City /ID# 247600
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104-4319
- Werving
- Children's Hospital of Philadelphia - Main /ID# 258071
-
-
Tennessee
-
Memphis, Tennessee, Verenigde Staten, 38103
- Voltooid
- Le Bonheur Children's Hospital /ID# 261084
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Access Clinical Trials, Inc. /ID# 248532
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78723-3079
- Werving
- UT Health Austin at Dell Children's Neurology Clinic /ID# 264082
-
Austin, Texas, Verenigde Staten, 78731
- Voltooid
- FutureSearch Trials of Neurology /ID# 247470
-
El Paso, Texas, Verenigde Staten, 79925-7945
- Voltooid
- 3A Research - East El Paso /ID# 248516
-
Friendswood, Texas, Verenigde Staten, 77546
- Werving
- Earle Research /ID# 248501
-
Contact:
- Site Coordinator
- Telefoonnummer: 281-218-8080
-
The Woodlands, Texas, Verenigde Staten, 77381
- Voltooid
- Family Psychiatry of The Woodlands /ID# 249727
-
Waxahachie, Texas, Verenigde Staten, 75165-1430
- Werving
- ClinPoint Trials /ID# 248540
-
-
Utah
-
Bountiful, Utah, Verenigde Staten, 84010-4968
- Werving
- Pantheon Clinical Research /ID# 251601
-
Clinton, Utah, Verenigde Staten, 84015
- Werving
- Alpine Research Organization - Clinton /ID# 276497
-
Salt Lake City, Utah, Verenigde Staten, 84124
- Werving
- Highland Clinical Research /ID# 247590
-
-
Virginia
-
Franklin, Virginia, Verenigde Staten, 23851
- Werving
- Office of Maria Ona /ID# 249738
-
-
Washington
-
Everett, Washington, Verenigde Staten, 98201
- Voltooid
- Core Clinical Research /ID# 249721
-
-
-
-
-
Mölnlycke, Zweden, 435 30
- Werving
- Vastra Gotealandsregionen Regionhalsan /ID# 248277
-
-
Stockholm County
-
Stockholm, Stockholm County, Zweden, 118 83
- Werving
- Sodersjukhuset /ID# 248279
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Weight is >= 20 kg (44 lbs) and < 135 kg (298 lbs).
- History of episodic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD) -3 (2018) for at least 6 months.
- Participant has to have 4 to 14 migraine days and < 15 headache days in the 28-day baseline period per eDiary.
- To be eligible for the PK substudy, participants must be 6 to 11 years of age (inclusive), with a history of migraine (consistent with a diagnosis according to the ICHD-3 [2018]) and per investigator judgment is appropriate to receive preventive treatment for migraine.
Exclusion Criteria:
- History of migraine brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).
- Have a current diagnosis of chronic migraine as defined by ICHD-3 (2018).
- Have a current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Open-Label PK Substudy: Atogepant Dose A (6-11 yrs)
Participants aged 6 to 11 will receive oral tablets of atogepant Dose A to determine appropriate dose for the 6-11 year old group in double-blind treatment period. |
Oral Tablet
Andere namen:
|
|
Experimenteel: Open-Label PK Substudy: Atogepant Dose B (6-11 yrs)
Participants aged 6 to 11 will receive oral tablets of atogepant Dose B to determine appropriate dose for the 6-11 year old group in double-blind treatment period. |
Oral Tablet
Andere namen:
|
|
Experimenteel: Double-Blind Treatment Period: High Dose Atogepant (12-17 yrs)
Participants aged 12 to 17 will receive oral tablets of high dose atogepant once a day for 12 weeks. |
Oral Tablet
Andere namen:
|
|
Placebo-vergelijker: Double-Blind Treatment Period: Placebo (12-17 yrs)
Participants aged 12 to 17 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks. |
Oral Tablet |
|
Experimenteel: Double-Blind Treatment Period: Low Dose Atogepant (12-17 yrs)
Participants aged 12 to 17 will receive oral tablets of low dose atogepant once a day for 12 weeks. |
Oral Tablet
Andere namen:
|
|
Experimenteel: Double-Blind Treatment Period: High Dose Atogepant (6-11 yrs)
Participants aged 6-11 will receive oral tablets of high dose atogepant once a day for 12 weeks. |
Oral Tablet
Andere namen:
|
|
Placebo-vergelijker: Double-Blind Treatment Period: Placebo (6-11 yrs)
Participants aged 6 to 11 will receive oral tablets of placebo-matching atogepant once a day for 12 weeks. |
Oral Tablet |
|
Experimenteel: Double-Blind Treatment Period: Low Dose Atogepant (6-11 yrs)
Participants aged 6-11 will receive oral tablets of low dose atogepant once a day for 12 weeks. |
Oral Tablet
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Mean Monthly Migraine Days
Tijdsspanne: Baseline (Week 0) through Week 12
|
A migraine day is defined as any calendar day on which a migraine occurs as per participant eDiary. Calendar days begin at midnight and last until 11:59 PM. |
Baseline (Week 0) through Week 12
|
|
Number of Participants Experiencing Adverse Events
Tijdsspanne: Baseline (Week 0) through Week 16
|
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. |
Baseline (Week 0) through Week 16
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline in Mean Monthly Headache Days
Tijdsspanne: Baseline (Week 0) through Week 12
|
A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g., ibuprofen, triptan) was used after the start of the headache, in which case no minimum duration will be specified. Calendar days begin at midnight and last until 11:59 PM. |
Baseline (Week 0) through Week 12
|
|
Change from Baseline in Mean Monthly Headache Days of at Least Moderate Severity
Tijdsspanne: Baseline (Week 0) through Week 12
|
A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication (e.g., ibuprofen, triptan) was used after the start of the headache, in which case no minimum duration will be specified. Calendar days begin at midnight and last until 11:59 PM. |
Baseline (Week 0) through Week 12
|
|
Change from Baseline in Mean Monthly Acute Medication Use Days
Tijdsspanne: Baseline (Week 0) through Week 12
|
An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) for the acute treatment of migraine. |
Baseline (Week 0) through Week 12
|
|
Percentage of Participants who Achieve at least a 50% Reduction in Average of Monthly Migraine Days
Tijdsspanne: Baseline (Week 0) to 3 Months
|
A migraine day is defined as any calendar day on which a migraine occurs as per participant eDiary. Calendar days begin at midnight and last until 11:59 PM. |
Baseline (Week 0) to 3 Months
|
|
Change from Baseline in the Pediatric Quality of Life Inventory (PedsQL) total score
Tijdsspanne: Baseline (Week 0) through Week 12
|
The PedsQL is a 23-item measure that evaluates quality of life in four areas of functioning: physical, emotional, social, and school functioning. The PedsQL yields a total quality of life score and two summary scores: Physical Health Summary Score and Psychosocial Health Summary Score. |
Baseline (Week 0) through Week 12
|
|
Change from baseline in the Pediatric Migraine Disability Assessment (PedMIDAS) total score
Tijdsspanne: Baseline (Week 0) through Week 12
|
The PedMIDAS scale evaluates the impact of headache on school performance, disability at home and social/sport function. The score is a composite of the total of 6 questions. |
Baseline (Week 0) through Week 12
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: ABBVIE INC., AbbVie
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- M21-201
- 2022-501100-94-00 (Andere identificatie: EU CT)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-tijdsbestek voor delen
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD-toegangscriteria voor delen
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .